^
    Back
    Association details:
    Biomarker:ALK G1202R
    Cancer:Non Small Cell Lung Cancer
    Drug:Zykadia (ceritinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Lung Cancer
    Title:

    Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study

    Published date:
    11/20/2021
    Excerpt:
    ASCEND-1 was an open-label, multicentre, phase 1, dose-escalation and expansion study of ceritinib (fasted) in ALK inhibitor (ALKi)-naïve or ALKi-pretreated patients with locally advanced or metastatic ALK + NSCLC..with the exception of one patient with a G1202R point mutation, all patients derived clinical benefit from ceritinib treatment.
    DOI:
    10.1016/j.lungcan.2021.11.007
    Trial ID:
    NCT01283516
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Drug Des Devel Ther
    Title:

    Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy

    Excerpt:
    In the ASCEND-1 study, a patient who was found with G1202R did not respond to ceritinib. The presence of this mutation confers resistance to ceritinib…
    DOI:
    10.2147/DDDT.S113500